valproic acid has been researched along with Baltic Myoclonic Epilepsy in 9 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Persistence of invalidating action myoclonus is a major problem." | 2.72 | Lack of efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht-Lundborg disease. ( Crespel, A; Gelisse, P; Genton, P, 2006) |
| "An increase in myoclonus, resulting from the progressive nature of the disease leads to significant disability in the majority of patients." | 1.51 | Unverricht-Lundborg disease: Clinical course and seizure management based on the experience of polish centers. ( Bosak, M; Lasek-Bal, A; Lukasik, M; Sulek, A; Żak, A, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Canafoglia, L | 1 |
| Ferlazzo, E | 2 |
| Michelucci, R | 1 |
| Striano, P | 1 |
| Magaudda, A | 3 |
| Gambardella, A | 1 |
| Pasini, E | 1 |
| Belcastro, V | 1 |
| Riguzzi, P | 1 |
| Fanella, M | 1 |
| Granata, T | 1 |
| Beccaria, F | 1 |
| Trentini, C | 1 |
| Bianchi, A | 1 |
| Aguglia, U | 1 |
| Panzica, F | 1 |
| Franceschetti, S | 1 |
| Kim, KH | 1 |
| Song, JS | 1 |
| Park, CW | 1 |
| Ki, CS | 1 |
| Heo, K | 1 |
| Lasek-Bal, A | 1 |
| Lukasik, M | 1 |
| Żak, A | 1 |
| Sulek, A | 1 |
| Bosak, M | 1 |
| Kälviäinen, R | 2 |
| Genton, P | 3 |
| Andermann, E | 1 |
| Andermann, F | 1 |
| Frucht, SJ | 1 |
| Schlit, AF | 1 |
| Gerard, D | 1 |
| de la Loge, C | 1 |
| von Rosenstiel, P | 1 |
| Korja, M | 1 |
| Soilu-Hänninen, M | 1 |
| Marttila, R | 1 |
| Parkkola, R | 1 |
| Rana, AQ | 1 |
| Ali, A | 1 |
| Böke, BN | 1 |
| Naito, H | 1 |
| Wachi, M | 1 |
| Gelisse, P | 1 |
| Crespel, A | 1 |
| Khyuppenen, J | 1 |
| Koskenkorva, P | 1 |
| Eriksson, K | 1 |
| Vanninen, R | 1 |
| Mervaala, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥16 Years) With Genetically Ascertained Unverricht[NCT00357669] | Phase 3 | 50 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥ 16 Years) With Genetically Ascertained Unverricht[NCT00368251] | Phase 3 | 56 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The range for Action Myoclonus Score (centrally read) is 0 (best) - 160 (worst). Percent change from Baseline = 100 X ((Baseline UMRS4 - Treatment UMRS4) / Baseline UMRS4). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: From Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 17.45 |
| Brivaracetam 5 mg/Day | -4.60 |
| Brivaracetam 150 mg/Day | 12.34 |
The range for Functional Disability Score is 0 (best) to 28 (worst). Percent change from Baseline = 100 X ((Baseline UMRS5 - Treatment UMRS5) / Baseline UMRS5). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 0.00 |
| Brivaracetam 5 mg/Day | 0.00 |
| Brivaracetam 150 mg/Day | 0.00 |
The range for Myoclonus Patient Questionnaire is 0 (best) to 44 (worst). Percent change from Baseline = 100 X ((Baseline UMRS1 - Treatment UMRS1) / Baseline UMRS1). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -9.68 |
| Brivaracetam 5 mg/Day | 0.00 |
| Brivaracetam 150 mg/Day | 5.41 |
The range for Stimulus Sensitivity Score is 0 (best) to 17 (worst). Percent change from Baseline = 100 X ((Baseline UMRS3 - Treatment UMRS3) / Baseline UMRS3). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 0.00 |
| Brivaracetam 5 mg/Day | 43.44 |
| Brivaracetam 150 mg/Day | 0.00 |
The Global Evaluation Scale Score (Investigator) ranges from 1 (Marked worsening) to 7 (Marked improvement). (NCT00368251)
Timeframe: End of Treatment Period (Week 14 or Early Discontinuation Visit)
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Marked improvement | Moderate improvement | Slight improvement | No change | Slight worsening | Moderate worsening | Marked worsening | |
| Brivaracetam 150 mg/Day | 11.1 | 11.1 | 33.3 | 33.3 | 5.6 | 5.6 | 0 |
| Brivaracetam 5 mg/Day | 10.0 | 0 | 30.0 | 50.0 | 10.0 | 0 | 0 |
| Placebo | 0 | 11.1 | 33.3 | 50.0 | 0 | 0 | 5.6 |
2 reviews available for valproic acid and Baltic Myoclonic Epilepsy
| Article | Year |
|---|---|
[Unverricht-Lundborg disease].
Topics: Adult; Cystatin B; Cystatins; Diagnosis, Differential; Humans; Male; Unverricht-Lundborg Syndrome; V | 2002 |
Clinical picture of EPM1-Unverricht-Lundborg disease.
Topics: Adolescent; Adult; Age of Onset; Animals; Anticonvulsants; Clonazepam; Cystatin B; Cystatins; Diagno | 2008 |
2 trials available for valproic acid and Baltic Myoclonic Epilepsy
| Article | Year |
|---|---|
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Metho | 2016 |
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Metho | 2016 |
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Metho | 2016 |
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Metho | 2016 |
Lack of efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht-Lundborg disease.
Topics: Acute Disease; Adult; Age of Onset; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, | 2006 |
5 other studies available for valproic acid and Baltic Myoclonic Epilepsy
| Article | Year |
|---|---|
Variable course of Unverricht-Lundborg disease: Early prognostic factors.
Topics: Adolescent; Adult; Age of Onset; Analysis of Variance; Anticonvulsants; Cathepsin B; Electroencephal | 2017 |
First Molecular Diagnosis of a Patient with Unverricht-Lundborg Disease in Korea.
Topics: Adult; Anticonvulsants; Blotting, Southern; Cystatin B; Female; Genetic Predisposition to Disease; H | 2018 |
Unverricht-Lundborg disease: Clinical course and seizure management based on the experience of polish centers.
Topics: Adult; Anticonvulsants; Brain; Electroencephalography; Female; Humans; Magnetic Resonance Imaging; M | 2019 |
T2-weighted high-intensity signals in the basal ganglia as an interesting image finding in Unverricht-Lundborg disease.
Topics: Adolescent; Adult; Anticonvulsants; Basal Ganglia; Body Mass Index; Brain Mapping; Case-Control Stud | 2010 |
Difficult differential diagnosis of Unverricht-Lundborg disease with spontaneous kinesogenic myoclonus and movement disorder.
Topics: Diagnosis, Differential; Female; Humans; Movement Disorders; Myoclonus; Treatment Outcome; Unverrich | 2012 |